Caplin Point Laboratories announced strong H1 FY26 results, with revenue up 11.9% YoY to ₹1098 Crores, surpassing FY21’s full-year revenue. H1 FY26 PAT reached ₹311 Crores, a 21.6% YoY increase, exceeding FY22’s full-year PAT. US market revenue grew by 27% YoY to ₹221 Crores. The company holds free cash reserves of ₹1,334 Crores and liquid assets of ₹2,358 Crores.
Financial Performance Highlights
Caplin Point Laboratories reported a robust financial performance for H1 FY26:
- Total Revenue: Increased by 11.9% YoY to ₹1098 Crores, surpassing FY21’s full-year revenue.
- Profit After Tax (PAT): Grew by 21.6% YoY to ₹311 Crores, exceeding FY22’s full-year PAT.
- US Market Revenue: Increased by 27% YoY, reaching ₹221 Crores.
- EBITDA Margin: Improved to 38.3% compared to 36.3% in H1 FY25.
Balance Sheet Strength
The company’s financial stability is highlighted by:
- Free Cash Reserves: Standing at ₹1,334 Crores.
- Liquid Assets: Totaling ₹2,358 Crores.
Strategic Developments
Key strategic moves and business updates include:
- API Unit Clearance: Received necessary clearances for the API unit for general category products at Vizag.
- Oncology API Site: Construction is underway at the Oncology API site in Thervoy, with completion expected within 12 months.
- EU GMP Reaudit: Successfully completed in October 2025 with NIL critical observations.
- US Market Expansion: CSU (Caplin Steriles USA Inc) launched 24 products to date and plans to launch 15+ more in FY26.
Leadership Changes
The company announced the following board appointments, effective November 5, 2025:
- Mr. Ashok Partheeban: Appointed as Additional Director and Vice-Chairman.
- Mr. Vivek Partheeban: Appointed as Additional Director and Vice-Chairman.
- Dr. K C John: Appointed as Independent Director.
First Quarter Financials
The company has showcased impressive figures for the Second quarter:
- Revenue from Operations: ₹534 crores
- Gross Profit: ₹323.7 crores
- EBITDA: ₹219.54 crores
- PAT: ₹160.23 crores
Source: BSE
